Dependence on the Anti-Hepatitis Virus Drug Market and Market Convergence
First written in FY2016. 11 of 25 entries say "Materialised", first in FY2018-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026SoftenedAnnual report
「However, contract testing services in the hepatitis field have recently declined substantially, and a recovery in the market is not expected.」
Contract testing services in the hepatitis field declined substantially, resulting in revenue of ¥66.409 million in the pharmacology field, or 90.8% of the previous year. Dependence on revenue from anti-hepatitis B drug-related business has declined substantially. - FY2025-H1MaterialisedAnnual report
「During the interim consolidated accounting period, research and development activity declined markedly among overseas pharmaceutical companies, the Group's major customers, as development programs were frequently cancelled and headcount reductions were implemented. Although inquiries continued to be received, order intake remained challenging and substantially below the previous year, while revenue also fell below the previous year because of the decline in new orders.」
The risk of dependence on development trends at major customers, including the anti-hepatitis drug market, has materialized as lower order intake and revenue following cancellations of development programs and headcount reductions at overseas pharmaceutical companies and a decline in new orders. - FY2024-Q3MaterialisedAnnual report
「In the pharmacology field, business remained sluggish and fell substantially below the same period of the previous year as cancellations and significant delays in anti-hepatitis B drug development by overseas pharmaceutical companies following budget reviews occurred one after another.」
States that repeated cancellations and significant delays in anti-hepatitis B drug development following budget reviews by overseas pharmaceutical companies caused the pharmacology field to fall substantially below the same period of the previous year. - FY2024-Q2MaterialisedAnnual report
「In the pharmacology field, order intake fell substantially below the same period of the previous year following the after-effects of cancellations and significant delays in anti-hepatitis B drug development resulting from budget reviews by overseas pharmaceutical companies.」
States that budget reviews by overseas pharmaceutical companies led to cancellations and significant delays in anti-hepatitis B drug development, causing order intake in the pharmacology field to fall substantially below the same period of the previous year. - FY2024-Q1MaterialisedAnnual report
「Order intake in the pharmacology field fell below the same period of the previous year because development delays and cancellations occurred in projects involving anti-hepatitis B drugs.」
States that development delays and cancellations occurred in anti-hepatitis B drug projects, causing order intake in the pharmacology field to fall below the same period of the previous year. - FY2023Disclosed dependence on anti-hepatitis B drug-related revenue of just under 50%.Annual report
「In the fiscal year ended March 2023, efficacy evaluation testing and other services for anti-hepatitis B virus drugs accounted for just under 50% of the Group's revenue. Because this is a limited market with only a limited number of pharmaceutical companies conducting development, the Group's performance also depends on the development activities of those pharmaceutical companies.」
Disclosed that testing related to anti-hepatitis B virus drugs accounts for just under 50% of revenue, while dependence on the limited market and customers' development activities continues. - FY2023-Q3MitigatedAnnual report
「Revenue substantially exceeded the same period of the previous year because contract testing for anti-hepatitis B drugs and mouse sales in overseas markets increased significantly.」
Although dependence on the market for anti-hepatitis B drugs remains, revenue substantially exceeded the same period of the previous year because contract testing for anti-hepatitis B drugs and mouse sales in overseas markets increased. - FY2023-Q2MitigatedAnnual report
「Revenue substantially exceeded the same period of the previous year because contract testing for anti-hepatitis B drugs and mouse sales in overseas markets increased significantly.」
Although dependence on the market for anti-hepatitis B drugs remains, revenue substantially exceeded the same period of the previous year because contract testing for anti-hepatitis B drugs and mouse sales in overseas markets increased. - FY2022MitigatedAnnual report
「Research and development activity at pharmaceutical companies and research institutions, the Group's major customers, recovered from the impact of the COVID-19 pandemic. Development of anti-hepatitis B drugs by overseas pharmaceutical companies was also active, and revenue remained firm in both the domestic and overseas markets.」
Although dependence on the market for anti-hepatitis B drugs remains, customer research and development activity and development by overseas pharmaceutical companies became more active, and revenue remained firm in both domestic and overseas markets. - FY2022-Q1MitigatedAnnual report
「Development of anti-hepatitis B drugs by overseas pharmaceutical companies was particularly active, and order intake increased substantially from the same period of the previous year.」
Although dependence on the market for anti-hepatitis B drugs remains, the disclosure states that development by overseas pharmaceutical companies became more active and order intake increased substantially. - FY2021ReframedAnnual report
「(2) Trends in new-drug development for anti-hepatitis virus drugs and market development in safety-related fields」
In addition to the existing risks of dependence on and convergence of the anti-hepatitis virus drug market, measures to develop the safety-related market have been incorporated into the same risk item, and the potential impact on performance if those measures fail to produce the expected results has been explicitly stated. - FY2020SoftenedAnnual report
「In the fiscal year ended March 2020, efficacy evaluation testing and other services for anti-hepatitis B virus drugs accounted for approximately 40% of the Group's revenue. Because this is a limited market with only a limited number of pharmaceutical companies conducting development, the Group's performance also depends on the development activities of those pharmaceutical companies.」
Dependence on revenue from testing related to anti-hepatitis B drugs declined from approximately 60% to approximately 40%. However, dependence on the limited market and pharmaceutical companies' development activities, as well as the risk of future market convergence, continues. - FY2020-Q3MaterialisedAnnual report
「In the pharmacology field, where hepatitis-related testing is currently the core business, stalled new-drug development at some overseas pharmaceutical companies affected order intake, which fell below the same period of the previous year. Revenue also remained below the previous year as several factors coincided, including scheduled contract testing being carried over to the following fiscal year.」
States that stalled new-drug development at some overseas pharmaceutical companies affected order intake, resulting in year-on-year declines in both order intake and revenue for the core hepatitis-related testing business. - FY2020-Q2MaterialisedAnnual report
「In the pharmacology field, where hepatitis-related testing is currently the core business, signs of stagnation emerged in the development activities of some overseas pharmaceutical companies, bringing the favorable order environment that had continued since the previous fiscal year to a pause. In addition, contract testing scheduled for the first half was delayed, resulting in revenue below the same period of the previous year.」
States that revenue from the core hepatitis-related testing business fell below the same period of the previous year because of stalled development by some overseas pharmaceutical companies and delays in contract testing. - FY2020-Q1MitigatedAnnual report
「In the pharmacology field, where hepatitis-related testing is currently the core business, inquiries have remained firm since the previous fiscal year. Order intake was at approximately the same level as the previous year because a large-scale project was pushed back to the second quarter, while revenue substantially exceeded the same period of the previous year.」
States that inquiries remained firm for hepatitis-related testing, with order intake at approximately the same level as the previous year because a large-scale project was delayed, while revenue substantially exceeded the previous year. Dependence on pharmaceutical companies' development activities remains, but business conditions improved during the quarter. - FY2019RestatedAnnual report
「In the fiscal year ended March 2019, efficacy evaluation testing and other services for anti-hepatitis B virus drugs accounted for approximately 60% of the Group's revenue. Because this is a limited market with only a limited number of pharmaceutical companies conducting development, the Group's performance also depends on the development activities of those pharmaceutical companies.」
Reconfirms that testing related to anti-hepatitis B drugs accounts for approximately 60% of revenue and that dependence on the limited market and pharmaceutical companies' development activities continues. - FY2019-Q3MitigatedAnnual report
「In the Group's current core business, hepatitis testing for pharmacological efficacy evaluation, inquiries have increased, particularly in overseas markets, as pharmaceutical companies have advanced the development of anti-hepatitis B drugs, and both revenue and order intake remained firm above the same period of the previous year.」
States that progress in the development of anti-hepatitis B drugs increased inquiries in overseas markets, and that revenue and order intake for hepatitis testing exceeded the same period of the previous year. - FY2019-Q2MaterialisedAnnual report
「In the Group's current core business, hepatitis testing for pharmacological efficacy evaluation, order intake, which had declined because of stalled drug development, has begun to recover, but some large-scale projects were pushed back to the second half, affecting revenue.」
States that order intake for hepatitis testing recovered, but some large-scale projects were pushed back to the second half, affecting revenue for the quarter. - FY2019-Q1MitigatedAnnual report
「In the Group's current core business, hepatitis testing for pharmacological efficacy evaluation, order intake, which had declined because of stalled drug development, has begun to recover, and both the domestic and overseas markets remained firm. In particular, overseas order backlog substantially exceeded the same period of the previous year because multiple large-scale projects were secured. The dependency risk remains, but the order environment improved during the quarter.」
States that order intake for hepatitis testing, which had declined because of stalled drug development, recovered, and that both the domestic and overseas markets remained firm. In overseas markets, order backlog also substantially exceeded the previous year following the acquisition of multiple large-scale projects. The dependency risk remains, but the order environment improved during the quarter. - FY2018MaterialisedAnnual report
「In the Group's current core business, hepatitis testing for pharmacological efficacy evaluation, the decline in order intake in overseas markets, where large-scale projects are concentrated, caused by the stagnation of drug development since the second half of the previous year lasted longer than expected, although the domestic market remained firm.」
States that dependence on hepatitis drug-related testing and the impact of stalled development by overseas pharmaceutical companies were reflected in full-year performance as a decline in overseas order intake. - FY2018-Q3MaterialisedAnnual report
「The Group's current core business, hepatitis testing for pharmacological efficacy evaluation, is in demand because the relevant virus infects only human liver cells, and PXB mice are recognized as a useful tool by many pharmaceutical companies and research institutions. Domestic revenue remained firm, mainly reflecting demand from universities and other institutions, but overseas revenue fell substantially below the same period of the previous year because of the impact of pharmaceutical companies' budget reviews.」
States that, although there was demand for the core hepatitis testing business, overseas revenue fell substantially below the same period of the previous year because of the impact of pharmaceutical companies' budget reviews. - FY2018-Q2MaterialisedAnnual report
「The Group's current core business, hepatitis testing for pharmacological efficacy evaluation, is in demand because the relevant virus infects only human liver cells, and PXB mice are recognized as a useful tool by many pharmaceutical companies and research institutions. However, overseas revenue fell substantially below the same period of the previous year because planned large-scale projects could not be won following pharmaceutical companies' budget reviews.」
States that, although there was demand for the core hepatitis testing business, planned large-scale projects could not be secured because pharmaceutical companies reviewed their budgets, causing overseas revenue to fall substantially below the same period of the previous year. - FY2018-Q1MaterialisedAnnual report
「The Group's current core business, hepatitis testing for pharmacological efficacy evaluation, is in demand because the relevant virus infects only human liver cells, and PXB mice are recognized as a useful tool by many pharmaceutical companies and research institutions. However, because the business is affected by pharmaceutical companies' development activities, overseas revenue fell below the same period of the previous year.」
States that, although there was demand for the core hepatitis testing business, overseas revenue fell below the same period of the previous year because it was affected by pharmaceutical companies' development activities. - FY2017SoftenedAnnual report
「In the fiscal year ended March 2017, efficacy evaluation testing and other services for anti-hepatitis B virus drugs accounted for approximately 60% of the Group's revenue. Because this is a limited market with only a limited number of pharmaceutical companies conducting development, the Group's performance also depends on the development activities of those pharmaceutical companies.」
Dependence on revenue from testing related to anti-hepatitis B virus drugs declined from approximately 70% to approximately 60% of revenue in the previous year. The risks associated with the limited market and market convergence remain. - FY2016First statedAnnual report
「In the fiscal year ended March 2016, efficacy evaluation testing and other services for anti-hepatitis B virus drugs accounted for approximately 70% of the Group's revenue. Because this is a limited market with only a limited number of pharmaceutical companies conducting development, the Group's performance also depends on the development activities of those pharmaceutical companies.」
Quantifies the Group's dependence on testing related to anti-hepatitis B virus drugs, which accounted for approximately 70% of revenue, and describes the possibility of market convergence.